Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Active Psoriatic Arthritis

NCT05623345 is registered in ClinicalTrials.gov with ACELYRIN Inc. as lead sponsor.

NCT NCT05623345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05623345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Active Psoriatic Arthritis
Lead sponsor
ACELYRIN Inc.
Phase
Phase 2/3
Overall status
Terminated
Start date
November 21, 2022
Completion date
August 8, 2024
Enrollment
351 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis